Agency Forms Undergoing Paperwork Reduction Act Review, 23818-23819 [2011-10256]
Download as PDF
<![CDATA[
23818
Federal Register / Vol. 76, No. 82 / Thursday, April 28, 2011 / Notices
DNA for substances studied by the NTP;
(2) integrates information derived from
studies of absorption, metabolism,
distribution, and excretion of test
substances within the body and the
development of mathematical models
that utilize this information in the
extrapolation and prediction of findings
across different species and exposure
conditions; (3) oversees analysis and
development of models using
information derived from studies of
gene expression in different tissues; (4)
incorporates systems biology
approaches; (5) reports results from all
these specialized toxicology studies; (6)
develops new methodologies for
toxicological assessments; and (7)
provides guidance on the proper
utilization of new types of toxicology
information in hazard identification,
hazard characterization, and regulatory
decision-making.
NTP Laboratory (NTPL) (N V56,
formerly, HN V56). Responsible for
providing laboratory capabilities and
support for the performance of agentspecific, targeted research directly
related to specific substances nominated
to the NTP, issues of central importance
to programs of the NTP, or the
development of new methods to
advance the scientific programs of the
NTP.
Delegations of Authority Statement:
All delegations and redelegations of
authority to officers and employees of
NIH that were in effect immediately
prior to the effective date of this
reorganization and are consistent with
this reorganization shall continue in
effect, pending further redelegation.
Dated: April 20, 2011.
Francis S. Collins,
Director.
[FR Doc. 2011–10318 Filed 4–27–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–11–10GI]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Evaluating Act Against AIDS Social
Marketing Campaign Phases Targeting
Consumers—New—National Center for
HIV/AIDS, Viral Hepatitis, STD and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
In response to the continued HIV
epidemic in our country, CDC has
launched Act Against AIDS (AAA), a 5year, multifaceted communication
campaign to reduce HIV incidence in
the United States. CDC plans to release
the campaign in phases, with some of
the phases running concurrently. Each
phase of the campaign will use mass
media and direct-to-consumer channels
to deliver HIV prevention and testing
messages. Some components of the
campaign will be designed to provide
basic education and increase awareness
of HIV/AIDS among the general public,
and others will be targeted to specific
subgroups or communities at greatest
risk of infection. The current study
addresses the need to assess the
effectiveness of these social marketing
messages aimed at increasing HIV
awareness and delivering HIV
prevention and testing messages among
at-risk populations.
This study will evaluate the AAA
social marketing campaign aimed at
increasing HIV/AIDS awareness,
increasing prevention behaviors, and
improving HIV testing rates among
consumers. The study will consist of a
quarterly tracking survey of AAA target
audiences to measure exposure to each
phase of the campaign and interventions
implemented under AAA. Each
extended survey will have a core set of
items asked in all rounds, as well as a
module of questions relating to specific
AAA activities and communication
initiatives that are occurring during a
given quarter. Each extended survey
sample will consist of 1,000
respondents selected from a
combination of sources, including a
national opt-in e-mail list sample and
respondent lists generated by
partnership organizations (e.g., the
National Urban League, the National
Medical Association). Participants will
self-administer the extended survey at
home on personal computers. The
research will include 12 data collections
over a 3-year period: four selfadministered quarterly extended
surveys per year over 3 years, with a
total of 12,000 respondents. There is no
cost to the respondents other than their
time. The total estimated annual burden
hours are 2667.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Form name
Individuals (male and female) aged 18 years
and older/Study Screener.
Individuals (male and female) aged 18 years
and older.
srobinson on DSKHWCL6B1PROD with NOTICES
Respondents
Study Screener ..............................................
20,000
1
2/60
Extended survey ............................................
4,000
1
30/60
VerDate Mar<15>2010
17:01 Apr 27, 2011
Jkt 223001
PO 00000
Frm 00032
Fmt 4703
Sfmt 9990
E:\FR\FM\28APN1.SGM
28APN1
Federal Register / Vol. 76, No. 82 / Thursday, April 28, 2011 / Notices
Dated: April 21, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–10256 Filed 4–27–11; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Granting of an Exclusive
License
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Technology
Transfer Office of the Centers for
Disease Control and Prevention (CDC),
located within the Department of Health
and Human Services (HHS), is
contemplating granting a worldwide
exclusive license to AES Raptor, LLC,
located in North Kansas City, Missouri.
Under this exclusive license, only AES
Raptor, LLC would be permitted to
commercialize the technology described
in the patent applications listed below.
CDC intends to grant rights to
commercialize this invention to no
other licensees. The patent rights in this
invention have been assigned to the
government of the United States of
America. The invention to be licensed
is:
Title: Barricade System and Barricade
Bracket for Use Therein, CDC Ref. #: I–
016–04, a safety rail system that
provides protection to individuals
working on inclined structures. The
system is designed to prevent
individuals from falls to a lower level.
U.S. Patent No.: 7,509,702.
U.S. Application No.: 11/257,472.
Filing date: 10/24/2005.
Canadian Application No.: 2,565,354.
Filing date: October 23, 2006.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
ADDRESSES: Requests for a copy of this
patent application, inquiries, comments,
and other materials relating to the
contemplated licenses should be
directed to Andrew Watkins, Director,
Technology Transfer Office, Centers for
Disease Control and Prevention (CDC),
4770 Buford Highway, Mailstop K–79,
Atlanta, GA 30341, telephone: (770)
488–8610; facsimile: (770) 488–8615.
srobinson on DSKHWCL6B1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:01 Apr 27, 2011
Jkt 223001
Applications for an exclusive license
filed in response to this notice will be
treated as objections to the grant of the
contemplated exclusive license. Only
written comments and/or applications
for a license which are received by CDC
within thirty days of this notice will be
considered. Comments and objections
submitted in response to this notice will
not be made available for public
inspection, and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2011–10257 Filed 4–27–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0588]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Exceptions or
Alternatives to Labeling Requirements
for Products Held by the Strategic
National Stockpile
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 31,
2011.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0614. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
23819
796–7651,
Juanmanuel.vilela@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Exceptions or Alternatives to Labeling
Requirements for Products Held by the
Strategic National Stockpile; Interim
Final Rule—(OMB Control Number
0910–0614)—Extension
Under the Public Health Service Act
(PHS Act), the Department of Health
and Human Services stockpiles medical
products that are essential to the health
security of the nation (see PHS Act,
section 319F–2, 42 U.S.C. 247d–6b).
This collection of medical products for
use during national health emergencies,
known as the Strategic National
Stockpile (SNS), is to ‘‘provide for the
emergency health security of the United
States, including the emergency health
security of children and other
vulnerable populations, in the event of
a bioterrorist attack or other public
health emergency.’’
It may be appropriate for certain
medical products that are or will be
held in the SNS to be labeled in a
manner that would not comply with
certain FDA labeling regulations given
their anticipated circumstances of use in
an emergency. However, noncompliance
with these labeling requirements could
render such products misbranded under
section 502 of the Federal Food, Drug,
and Cosmetic Act (the FD& C Act) (21
U.S.C. 352).
In the Federal Register of December
28, 2007 (72 FR 73589), FDA published
an interim final rule entitled
‘‘Exceptions or Alternatives to Labeling
Requirements for Products Held by the
Strategic National Stockpile.’’ In the
interim final rule, FDA issued
regulations under §§ 201.26, 610.68,
801.128, and 809.11 (21 CFR 201.26,
610.68, 801.128, and 809.11), which
allow the appropriate FDA Center
Director to grant a request for an
exception or alternative to certain
regulatory provisions pertaining to the
labeling of human drugs, biological
products, medical devices, and in vitro
diagnostics that currently are or will be
included in the SNS if certain criteria
are met. The appropriate FDA Center
Director may grant an exception or
alternative to certain FDA labeling
requirements if compliance with these
labeling requirements could adversely
affect the safety, effectiveness, or
availability of products that are or will
be included in the SNS. An exception
or alternative granted under the
E:\FR\FM\28APN1.SGM
28APN1
]]>Agencies
[Federal Register Volume 76, Number 82 (Thursday, April 28, 2011)]
[Notices]
[Pages 23818-23819]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10256]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30-Day-11-10GI]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-5806.
Written comments should be received within 30 days of this notice.
Proposed Project
Evaluating Act Against AIDS Social Marketing Campaign Phases
Targeting Consumers--New--National Center for HIV/AIDS, Viral
Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
In response to the continued HIV epidemic in our country, CDC has
launched Act Against AIDS (AAA), a 5-year, multifaceted communication
campaign to reduce HIV incidence in the United States. CDC plans to
release the campaign in phases, with some of the phases running
concurrently. Each phase of the campaign will use mass media and
direct-to-consumer channels to deliver HIV prevention and testing
messages. Some components of the campaign will be designed to provide
basic education and increase awareness of HIV/AIDS among the general
public, and others will be targeted to specific subgroups or
communities at greatest risk of infection. The current study addresses
the need to assess the effectiveness of these social marketing messages
aimed at increasing HIV awareness and delivering HIV prevention and
testing messages among at-risk populations.
This study will evaluate the AAA social marketing campaign aimed at
increasing HIV/AIDS awareness, increasing prevention behaviors, and
improving HIV testing rates among consumers. The study will consist of
a quarterly tracking survey of AAA target audiences to measure exposure
to each phase of the campaign and interventions implemented under AAA.
Each extended survey will have a core set of items asked in all rounds,
as well as a module of questions relating to specific AAA activities
and communication initiatives that are occurring during a given
quarter. Each extended survey sample will consist of 1,000 respondents
selected from a combination of sources, including a national opt-in e-
mail list sample and respondent lists generated by partnership
organizations (e.g., the National Urban League, the National Medical
Association). Participants will self-administer the extended survey at
home on personal computers. The research will include 12 data
collections over a 3-year period: four self-administered quarterly
extended surveys per year over 3 years, with a total of 12,000
respondents. There is no cost to the respondents other than their time.
The total estimated annual burden hours are 2667.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Individuals (male and female) aged 18 Study Screener.......... 20,000 1 2/60
years and older/Study Screener.
Individuals (male and female) aged 18 Extended survey......... 4,000 1 30/60
years and older.
----------------------------------------------------------------------------------------------------------------
[[Page 23819]]
Dated: April 21, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. 2011-10256 Filed 4-27-11; 8:45 am]
BILLING CODE P
